Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC

J Thorac Oncol. 2016 Aug;11(8):e99-e101. doi: 10.1016/j.jtho.2016.04.002. Epub 2016 Apr 12.

Authors

Francesco Gelsomino¹, Valentina Ambrosini², Barbara Melotti³, Francesca Sperandi³, Andrea Ardizzoni³

Affiliations

¹ Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy. Electronic address: francesco.gelsomino@aosp.bo.it.
² Nuclear Medicine Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.
³ Medical Oncology Unit, Policlinico S.Orsola-Malpighi, Bologna, Italy.

PMID: 27079186
DOI: 10.1016/j.jtho.2016.04.002

No abstract available

Publication types

Case Reports

MeSH terms

Anaplastic Lymphoma Kinase
Bone Neoplasms / chemically induced
Bone Neoplasms / genetics
Bone Neoplasms / secondary*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Disease Progression
Gene Rearrangement*
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Middle Aged
Osteoblasts / drug effects
Osteoblasts / pathology*
Prognosis
Pyrimidines / therapeutic use*
Receptor Protein-Tyrosine Kinases / genetics*
Sulfones / therapeutic use*
Tomography, X-Ray Computed

Substances

Pyrimidines
Sulfones
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases
ceritinib